Natural Product (NP) Details

General Information of the NP (ID: NP2206)
Name
Taxifolin
Synonyms
TAXIFOLIN; 480-18-2; (+)-Taxifolin; dihydroquercetin; Distylin; Taxifoliol; (2R,3R)-Dihydroquercetin; (+)-Dihydroquercetin; TAXIFOLIN-(+); Lariksin; Lavitol; 24198-97-8; taxifolin (dihydroquercetin); (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; UNII-9SOB9E3987; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; (2R,3R)-Taxifolin; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; (+/-)-Taxifolin hydrate; 3,5,7,3',4'-Pentahydroxyflavanone; (+/-)-Taxifolin; 2,3-Dihydroquercetin; (2R-trans)-2-(3,4-Dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4-benzopyrone; (2R,3R)-(+)-Taxifolin; 17654-26-1; CHEBI:17948; 9SOB9E3987; MFCD00006845; Flavanone, 3,3',4',5,7-pentahydroxy-; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one; Diquertin; (?)-Taxifolin; 3,3',4',5,7-Pentahydroxyflavanone; Flamena D; (2R,3R)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one; DQH; SMR000466389; trans-Dihydroquercetin; (+)-trans-Taxifolin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-; Dihydroquercetin hydrate; CCRIS 9292; (+)-(2R,3R)-dihydroquercetin; Taxifolin (Tax); EINECS 207-543-4; (+)-trans Taxifolin; (2R,3R)-TRANS-DIHYDROQUERCETIN; BRN 0093548; Taxifolin, (+/-)-; Dihydroquercetin, (+/-)-; SCHEMBL39786; 5-18-05-00451 (Beilstein Handbook Reference); MLS000759539; MLS001066341; MLS001074712; MLS001424044; MLS002153142; BIDD:ER0483; Taxifolin, analytical standard; Flavone, 2,3-dihydro-3,3',4',5,7-pentahydroxy-; MEGxp0_000741; DTXSID8022450; ACon1_000239; BDBM212435; DTXSID301017215; HMS2051M22; HMS2234L14; HY-N0136; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chroman-4-one; AC-935; MFCD11044454; s2366; AKOS015965399; ZINC100018343; CCG-100909; CS-3365; DB02224; KS-1312; MCULE-2394173874; MCULE-2692728789; NC00159; NCGC00016024-08; NCGC00180750-01; 20254-28-8; AS-17723; (+)-3,3',4',5,7-Pentahydroxyflavanone; 3,3',4',5,7-Pentahydroxyflavanone hydrate; SW197539-2; V1551; C01617; (2R,3R)-3,5,7,3',4'-Pentahydroxyflavanone; Q412191; SR-01000759385; Flavanone, 3,3',4',5,7-pentahydroxy-, (R,R)-; J-011205; SR-01000759385-6; Taxifolin, primary pharmaceutical reference standard; F40AB773-26FA-4112-A46D-DC970AF64BC1; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R)-trans-; Flavanone, 3,3',4',5,7-pentahydroxy-, trans-(+)-; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R,3R)-(+)-; UNII-EAS93SC1VS component CXQWRCVTCMQVQX-LSDHHAIUSA-N; rel-(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-chromen-4-one, (2R-trans)-; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R-trans)-; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, trans-(+/-)-
    Click to Show/Hide
Species Origin Larix gmelinii ...     Click to Show/Hide
Larix gmelinii
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Pinopsida
Family: Pinaceae
Genus: Larix
Species: Larix gmelinii
Disease Breast cancer [ICD-11: 2C60] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H12O7
PubChem CID
439533
Canonical SMILES
C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
InChI
1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1
InChIKey
CXQWRCVTCMQVQX-LSDHHAIUSA-N
CAS Number
CAS 480-18-2
ChEBI ID
CHEBI:17948
Herb ID
HBIN045672
SymMap ID
SMIT00564
TCMSP ID
MOL004576
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Sorafenib      Renal cell carcinoma     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression FOXP3  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Sor-Tau combination led to FOXP3 down-regulation in hepatic cancer cells (HepG2) and improved therapeutic efficacy of sorafenib treated HCC.
          Dapagliflozin      Type 2 diabetes mellitus     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression GABPA  Molecule Info 
Pathway MAP
Up-regulation Expression JNK1  Molecule Info 
Pathway MAP
Up-regulation Expression p105  Molecule Info 
Pathway MAP
Up-regulation Expression TLR4  Molecule Info 
Pathway MAP
                    In-vivo Model Male rats were used to establish colistin-induced nephrotoxicity animal model in this study.
                    Experimental
                    Result(s)		 Combined use of taxifolin and dapagliflozin may confer a therapeutic tool for attenuation of colistin-induced nephrotoxicity.
Target and Pathway
Target(s) Apolipoprotein E (APOE)  Molecule Info  [4]
Triggering receptor expressed on monocytes 2 (TREM2)  Molecule Info  [4]
KEGG Pathway Alzheimer's disease Click to Show/Hide
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
2 FSH Signaling Pathway
3 Wnt Signaling Pathway
Reactome Chylomicron-mediated lipid transport Click to Show/Hide
2 HDL-mediated lipid transport
3 Scavenging by Class A Receptors
4 Retinoid metabolism and transport
WikiPathways Statin Pathway Click to Show/Hide
2 Apoptosis-related network due to altered Notch3 in ovarian cancer
3 Binding and Uptake of Ligands by Scavenger Receptors
4 Visual phototransduction
5 Lipid digestion, mobilization, and transport
6 Alzheimers Disease
7 Vitamin B12 Metabolism
References
Reference 1 Taxifolin inhibits breast cancer cells proliferation, migration and invasion by promoting mesenchymal to epithelial transition via Beta-catenin signaling. Life Sci. 2019 Sep 1;232:116617.
Reference 2 Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects. Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3007-3013.
Reference 3 Effect of taxifolin/dapagliflozin combination on colistin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2021 Apr 22;9603271211010906.
Reference 4 Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2019 May 14;116(20):10031-10038.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link